InsiderTrades.com logo

INDP Insider Trading

Insider Ownership Percentage: 29.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Indaptus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Indaptus Therapeutics Share Price & Price History

Current Price: $0.47
Price Change: ▼ Price Decrease of -0.026 (-5.24%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for INDP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$0.47Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Indaptus Therapeutics (NASDAQ:INDP)

7.06% of Indaptus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INDP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal InflowsTotal Outflows
Indaptus Therapeutics logo
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Read More on Indaptus Therapeutics

Today's Range

Now: $0.47
Low: $0.47
High: $0.53

50 Day Range

MA: $0.78
Low: $0.47
High: $0.95

52 Week Range

Now: $0.47
Low: $0.47
High: $3.10

Volume

174,897 shs

Average Volume

140,433 shs

Market Capitalization

$6.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Who are the company insiders with the largest holdings of Indaptus Therapeutics?

Indaptus Therapeutics' top insider shareholders include:
  1. Glen R Anderson (Major Shareholder)
Learn More about top insider investors at Indaptus Therapeutics.